AIMS: We investigated the pharmacokinetics and safety profile of oral ganciclovir coadministered with trimethoprim in HIV-and CMV-seropositive patients. METHODS: In an open-label, randomized, 3-way crossover study, 12 adult males receivedoral ganciclovir 1000 mg every 8h, oral trimethoprim 200 mg once daily, or both drugs concomitantly in a sequence of three 7-day treatment periods. Pharmacokinetic parameters were determined and adverse events recorded for each treatment. RESULTS: The presence of trimethoprim significantly decreased CLr (12.9%, P=0.0068) and increased t1/2 (18.1%, P=0.0378) of ganciclovir. However, these changes are unlikely to be clinically meaningful. There were no statistically significant changes in trimethoprim pharmacokinetic parameters in the presence of ganciclovir, with the exception of a 12.7% increase in Cmin. Ganciclovir was well tolerated when administered alone or in combination with trimethoprin. CONCLUSIONS: There was no clinically significant pharmacokinetic interaction between oral ganciclovir and trimethoprim when coadministered.
RCT Entities:
AIMS: We investigated the pharmacokinetics and safety profile of oral ganciclovir coadministered with trimethoprim in HIV-and CMV-seropositivepatients. METHODS: In an open-label, randomized, 3-way crossover study, 12 adult males received oral ganciclovir 1000 mg every 8h, oral trimethoprim 200 mg once daily, or both drugs concomitantly in a sequence of three 7-day treatment periods. Pharmacokinetic parameters were determined and adverse events recorded for each treatment. RESULTS: The presence of trimethoprim significantly decreased CLr (12.9%, P=0.0068) and increased t1/2 (18.1%, P=0.0378) of ganciclovir. However, these changes are unlikely to be clinically meaningful. There were no statistically significant changes in trimethoprim pharmacokinetic parameters in the presence of ganciclovir, with the exception of a 12.7% increase in Cmin. Ganciclovir was well tolerated when administered alone or in combination with trimethoprin. CONCLUSIONS: There was no clinically significant pharmacokinetic interaction between oral ganciclovir and trimethoprim when coadministered.
Authors: S A Spector; D F Busch; S Follansbee; K Squires; J P Lalezari; M A Jacobson; J D Connor; D Jung; A Shadman; B Mastre Journal: J Infect Dis Date: 1995-06 Impact factor: 5.226
Authors: J Y Chatton; A Munafo; J P Chave; F Steinhäuslin; F Roch-Ramel; M P Glauser; J Biollaz Journal: Br J Clin Pharmacol Date: 1992-12 Impact factor: 4.335
Authors: W L Drew; D Ives; J P Lalezari; C Crumpacker; S E Follansbee; S A Spector; C A Benson; D N Friedberg; L Hubbard; M J Stempien Journal: N Engl J Med Date: 1995-09-07 Impact factor: 91.245
Authors: N Perrottet; C Csajka; M Pascual; O Manuel; F Lamoth; P Meylan; J D Aubert; J P Venetz; P Soccal; L A Decosterd; J Biollaz; T Buclin Journal: Antimicrob Agents Chemother Date: 2009-03-23 Impact factor: 5.191